Scarica l'app Stockscreener
9.4877
1.97%
-0.1823
Precedente Chiudi:
$9.67
Aprire:
$9.82
Volume 24 ore:
134.56K
Relative Volume:
0.45
Capitalizzazione di mercato:
$308.13M
Reddito:
-
Utile/perdita netta:
$-62.31M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-12.39%
1M Prestazione:
-22.36%
6M Prestazione:
-39.11%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.226
$10.17
Intervallo di 1 settimana:
$9.226
$11.17
Portata 52W:
$9.226
$22.33
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Nome
Lexeo Therapeutics Inc
Settore
Industria
Telefono
(212) 547-9879
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Objective long/short (LXEO) Report - Stock Traders Daily
Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Price Target at $22.14 - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World
Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR
The Globe and Mail - The Globe and Mail
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
Top investors say Lexeo Therapeutics Inc. (LXEO) ticks everything they need - SETE News
The Lexeo Therapeutics Inc. (LXEO) had a good session last reading, didn’t it? - US Post News
Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 16.9% - MarketBeat
Trading (LXEO) With Integrated Risk Controls - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts - MarketBeat
Chardan Capital Comments on Lexeo Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:LXEO) - MarketBeat
Vanguard Group Inc. Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Stifel maintains 'Buy' on Lexeo stock, confident amid trial progress By Investing.com - Investing.com Canada
Chardan Capital Weighs in on Lexeo Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Reaffirmed by Chardan Capital - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - MarketBeat
Q3 2024 Earnings Estimate for Lexeo Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Lexeo Therapeutics CEO sells $57.6k in company stock By Investing.com - Investing.com Australia
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $21.00 at HC Wainwright - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares of Stock - Defense World
Lexeo Therapeutics CEO sells $57.6k in company stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given New $21.00 Price Target at HC Wainwright - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Comparing Cognition Therapeutics (NASDAQ:CGTX) & Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - InvestorPlace
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - MSN
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - StockTitan
Lexeo Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
American International Group Inc. Invests $79,000 in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World
Janus Henderson Group PLC Acquires 210,047 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Robert W. Baird gives an Outperform recommendation for Lexeo Therapeutics Inc. (LXEO) - Knox Daily
BNP Paribas Financial Markets Takes Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
LXEO (Lexeo Therapeutics Inc.) may reap gains as insiders became active recently - Knox Daily
Lexeo Therapeutics Inc. (LXEO) deserves closer scrutiny - US Post News
Lexeo Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.59) Per Share, Leerink Partnrs Forecasts (NASDAQ:LXEO) - Defense World
Q3 2024 EPS Estimates for Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Decreased by Analyst - MarketBeat
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates - Yahoo Finance
Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data - Markets Insider
Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key CompaniesRetrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics - India Shorts
Lexeo Therapeutics Inc Azioni (LXEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexeo Therapeutics Inc Azioni (LXEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
Sep 10 '24 |
Sale |
10.65 |
5,000 |
53,274 |
120,695 |
1.26%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):